Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04825990
Title Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer (POINT)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Gruppo Oncologico del Nord-Ovest
Indications

nasopharynx carcinoma

Therapies

Olaparib + Pembrolizumab

Age Groups: senior | adult
Covered Countries ITA


No variant requirements are available.